Moreover, as a corollary, antiangiogenic drugs against VEGFR suppressed Treg proliferation in colorectal cancer, making these drugs an attractive target to inhibit tumor-infiltrating Tregs thus providing a new avenue for tumor treatment (Terme et al., 2013; reviewed in Hu and Jiang, 2017). This evidence concerns the gene KDR and neoplasm.